Integrative Care Strategies for Weight Loss from Obesity

Uncover the benefits of integrative care for obesity in addressing weight issues through a multifaceted approach to health.

Abstract

In this educational post, I present a clinician-centered, evidence-based guide to obesity care, focusing on the critical interplay between metabolic health and reproductive, sleep, and psychiatric considerations. Drawing from the latest research and my clinical experience, I outline practical strategies for assessing and treating conditions like polycystic ovary syndrome (PCOS), insulin resistance, and the complex health challenges surrounding pregnancy. We will delve into the profound impact of chronic stress, sleep disorders, and disordered eating on weight, exploring the neuroendocrine pathways and circadian biology that drive metabolic dysfunction. I will detail how we use practical screening tools, targeted nutrition, movement strategies, behavioral therapies, and modern pharmacotherapies, including GLP-1/GIP receptor agonists and off-label metformin. Throughout this guide, I will share comprehensive, first-person case journeys that illustrate how our multidisciplinary team at Injury Medical Clinic PA in El Paso, Texas, integrates integrative chiropractic care, functional medicine, and medical oversight to restore health. This post will also highlight the collaborative model between myself, Dr. Alexander Jimenez, and our Medical Director, Dr. Maria Guadalupe Cardenas, MD, demonstrating how we coordinate chiropractic biomechanics, internal medicine, personal injury care, and rehabilitation to deliver comprehensive, evidence-based outcomes for our patients.

My Role, Our Team, and Our Integrative Model

Hello, I’m Dr. Alex Jimenez. With a diverse background as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and Board-Certified Family Nurse Practitioner (FNP-BC), along with advanced certifications in Functional Medicine (CFMP, IFMCP, ATN, CCST), I am committed to a holistic and integrative approach to patient care. At our El Paso-based practice, Injury Medical Clinic PA—also known as Mission Plaza Injury Medical Clinic—we have created a unique, multidisciplinary environment where different specialties collaborate for the patient’s best interest.

A cornerstone of our practice is the collaboration between Dr. Maria Guadalupe Cardenas, MD, and me. Dr. Cardenas is Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933) and brings over 40 years of invaluable experience as our Medical Director and Collaborative Physician. This partnership is common in integrative and injury care clinics and allows us to blend the best of chiropractic care, functional medicine, rehabilitation, and traditional medical oversight. Dr. Cardenas guides medical protocols, diagnostics, complex comorbidity management, and pharmacotherapy, while I direct the spinal, neuromuscular, and functional interventions.

What this coordinated model delivers:

• Medical oversight from a seasoned internist (Dr. Cardenas) for metabolic, endocrine, cardiometabolic, and pharmacologic decisions.
• Integrative chiropractic care (Dr. Jimenez) focusing on neuromusculoskeletal optimization, movement restoration, autonomic balance, and rehabilitation to support weight loss and cardiometabolic health.
• Functional medicine diagnostics and targeted lifestyle interventions to address root causes, including inflammation, insulin resistance, circadian disruption, and gut dysbiosis.
• Personal injury care and rehabilitation, recognizing that pain, reduced mobility, and impaired biomechanics often stall weight-management progress.

In my clinical observations and practice data (see wellnessdoctorrx.com and my LinkedIn), patients experience improved adherence, better functional outcomes, and lower pain burdens when we link metabolic care with neuromusculoskeletal optimization and lifestyle medicine. This integrated approach respects the interconnected physiology of body systems and aligns with modern evidence-based obesity care.

Reproductive Health in Obesity: PCOS, Insulin Resistance, and Lifespan Risk

Understanding PCOS as a Chronic Disease Across the Lifespan

In women aged 18–40, polycystic ovary syndrome (PCOS) is the most common endocrine disorder, affecting approximately 10% of reproductive-age women. PCOS should be framed as a chronic, multisystem condition with significant metabolic and cardiometabolic implications that persist beyond reproductive years. Clinically and mechanistically, PCOS lives at the intersection of obesity, insulin resistance, hyperandrogenism, and low-grade inflammation, and these factors feed forward into long-term cardiometabolic risk.

Key points I emphasize during evaluation:

• PCOS prevalence increases with obesity; 60–80% of women with PCOS exhibit overweight/obesity.
• Genetic and ethnic factors influence severity; women of Spanish, Native American, and Mexican descent show higher prevalence.
• Lifespan perspective: beyond menstrual and fertility issues, PCOS confers elevated risks for type 2 diabetes, dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease (MASLD), obstructive sleep apnea, and cardiovascular disease.

Physiological mechanisms:

• Insulin resistance (IR) drives hyperinsulinemia, which stimulates theca cell androgen production, elevates luteinizing hormone (LH), and disrupts ovulatory signals. IR amplifies adipose lipolysis and hepatic VLDL output, feeding dyslipidemia and ectopic fat deposition. Chronic low-grade inflammation from visceral adiposity (via IL-6, TNF-α, and CRP) worsens insulin signaling and dysregulates ovarian steroidogenesis. These overlapping circles—obesity, IR, and PCOS—are physiologically inseparable and clinically synergistic.

Diagnostic Approach: Applying Rotterdam Criteria Clinically

I use the Rotterdam 2003 criteria as the practical diagnostic framework: the presence of two out of three findings, after exclusion of other etiologies:

• Hyperandrogenism: clinical signs (acne, hirsutism, androgenic alopecia) and/or laboratory evidence.
• Ovulatory dysfunction: amenorrhea or oligomenorrhea.
• Polycystic ovarian morphology on ultrasound.

This framework captures the heterogeneous expression of PCOS and remains the most widely used, allowing me to diagnose at the point of care when hyperandrogenism and ovulatory dysfunction are present.

Treatment Priorities: Weight Reduction, Insulin Sensitization, and Endometrial Protection

I prioritize treating obesity early because even modest weight loss provides measurable reproductive and metabolic benefits. A 5–7% weight reduction can restore menstrual cyclicity and spontaneous ovulation, while lowered insulin levels reduce ovarian androgen synthesis and decrease progression to prediabetes.

Therapeutic pillars and reasoning:

• Nutrition for IR: I teach patients that IR is a spectrum of carbohydrate intolerance. I recommend prioritizing protein (with natural fats) and fiber-rich vegetables and fruit, while minimizing ultra-processed starches, sweets, refined grains, and alcohol, which disproportionately spike insulin.
• Physical activity for insulin sensitivity: Brief, 10–15-minute sessions, performed 2–3 times daily, improve skeletal muscle glucose uptake through AMPK activation and GLUT4 translocation. Resistance training adds dual benefits by increasing lean mass and exerting anti-inflammatory effects.
• Metformin (off-label in non-diabetic IR): Under Dr. Cardenas’s medical direction, we frequently prescribe extended-release metformin 500 mg, titrating slowly. Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, which, in PCOS, lowers insulin levels, downregulates ovarian androgen production, and supports ovulatory restoration.
• Anti-obesity pharmacotherapy: GLP-1 receptor agonists/dual incretin agents are often preferred due to robust adiposity reduction, appetite regulation, and improved glycemic control. Mechanistically, they enhance glucose-dependent insulin secretion and reduce glucagon secretion, thereby improving hepatic glucose handling.
• Endometrial protection: In women with chronic anovulation, we ensure combined oral contraceptives (unless contraindicated) to reduce endometrial proliferation risk. Spironolactone may be added for hyperandrogenic symptoms, with attention to teratogenicity prevention.

Since fertility can return quickly with metabolic improvements, I discuss contraception early to prevent unplanned pregnancy.

Obesity and Pregnancy: The Generational Echo of Metabolic Health

Pregnancy in the setting of obesity requires sensitive care and vigilant risk management. As healthcare providers, it is our responsibility to address the significant health risks that can arise, particularly when a mother begins her pregnancy with obesity.

Key Risks, Mechanisms, and The Power of Preconception Care

Conditions like gestational hypertension and preeclampsia are not just transient issues; they carry severe consequences, including increased likelihood of miscarriage, preterm births, and thromboembolism for the mother. Mothers with obesity also face a higher probability of a cesarean section, with amplified risks of infection, bleeding, and poor wound healing.

One of the most compelling reasons to address parental health before conception is the science of epigenetics. It is now well-established that both maternal and paternal adiposity can epigenetically program their offspring for a higher risk of obesity, cardiovascular disease, and type 2 diabetes. This is a critical point we stress: the father’s health is equally important. By improving a woman’s weight and metabolic health before she conceives, we can interrupt this pattern of generational obesity and make a monumental impact on the well-being of generations to come.

Benefits of Preconception Weight Reduction:

• For the Mother: It improves the chances of conception, reduces pregnancy complications, and eases the physical and emotional challenges of pregnancy and childbirth.
• For the Child: It sets the stage for a healthier life, reducing the inherited risk of metabolic disease.

Evidence shows that lifestyle interventions (nutrition, physical activity) combined with medications like Metformin can lead to substantial weight loss, lowered insulin resistance, and a remarkable 20-30% decrease in the rate of gestational diabetes and a 20-40% decrease in macrosomia (oversized baby).

An Integrative Approach to Preconception Health

At our clinic, we use a multifaceted approach:

• Lifestyle and Foundational Health: We start with a nutrition plan focused on reducing insulin resistance, promoting regular physical activity, and optimizing sleep and managing stress.
• Judicious Use of Medications: Under Dr. Cardenas’s direction, we may use Metformin, which can often be safely continued into pregnancy. Powerful obesity medications like GLP-1 agonists (e.g., Semaglutide, Tirzepatide) can achieve substantial weight loss. Still, they must be discontinued before attempting pregnancy, with a recommended two-month washout period for both men and women.
• Compassionate Care: I address weight stigma explicitly, advocating for respectful, patient-centered care, as discrimination and humiliation in healthcare settings harm engagement and outcomes.

Navigating Breastfeeding with Obesity

Breastfeeding offers immense benefits, yet women with obesity have lower rates of initiation and duration due to physical challenges (e.g., difficult labor, positioning issues) and psychological hurdles like internalized weight bias. Our role is to provide proactive support by educating women, assessing barriers, and connecting them with resources such as lactation specialists. Importantly, we emphasize that a mother must eat enough to maintain an adequate milk supply; severe calorie restriction during breastfeeding is not advisable.

Stress, Sleep, and Eating Disorders: The Metabolic Connection

In my practice, I frequently see how chronic stress, mental health conditions, sleep disorders, and disordered eating converge to drive metabolic dysfunction and weight challenges.

Stress, Neuroinflammation, and Weight: Why It’s All Connected

Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, increasing cortisol and catecholamine levels. Over time, this contributes to low-grade systemic inflammation, insulin resistance, and visceral adiposity. Elevated cortisol levels drive gluconeogenesis and appetite, while inflammatory cytokines disrupt leptin and insulin signaling, thereby impairing satiety and glycemic control. This HPA dysregulation also alters brain function, worsening memory, focus, and executive control, which increases cravings and emotional eating.

Sleep and Weight Health: The Metabolic Links

Sleep is a pillar of metabolic health, and its disturbance is both a driver and a consequence of obesity. The recommended minimum is 7–9 hours nightly.

• Obstructive sleep apnea (OSA), common in obesity, increases sympathetic drive, elevating cortisol and worsening insulin resistance and blood pressure. Recurrent hypoxia drives oxidative stress and inflammation. Recent evidence from trials of tirzepatide for OSA in patients with obesity showed a >60% reduction in apnea events and ~18–20% total body weight reduction, underscoring the power of weight management to address root causes.
• Short sleep impairs leptin and ghrelin balance, increasing hunger while reducing insulin sensitivity.
• Shift work disorder, a misalignment between circadian rhythms and work demands, can cause metabolic syndrome and weight gain via hormone disruption.

Our clinical strategy involves screening for OSA (STOP-BANG, Epworth Sleepiness Scale) and, when indicated, referring for sleep studies. We also provide behavioral sleep interventions and management strategies for shift work, including sleep scheduling and hygiene.

Psychiatric Conditions and Disordered Eating That Influence Weight

Mental health diagnoses and their treatments can be weight-promoting. Our approach emphasizes screening, collaboration with mental health providers, and the selection of medications that align with weight goals.

Key conditions and our screening tools:

• Anxiety and Depression: Screen with PHQ-9 and GAD-7.
• Bipolar Disorder: Screen with MDQ (Mood Disorder Questionnaire).
• ADD/ADHD: Screen with ASRS (Adult ADHD Self-Report Scale).
• Eating Disorders: Screen with ESP (Eating Disorder Screen for Primary Care) and SCOFF. Eating disorders have among the highest psychiatric mortality rates, and we must recognize red flags like significant weight fluctuations, GI complaints, and preoccupation with weight and calories.

We distinguish between eating disorders (e.g., anorexia, bulimia, binge eating disorder) and disordered eating, which includes problematic patterns that don’t meet full criteria but are common in individuals with obesity. In either case, early intervention, referrals to specialists, and careful medication selection are crucial. For example, for a patient with binge eating disorder, we might consider lisdexamfetamine or a GLP-1 agonist to reduce binge behaviors. We also coordinate with psychiatry to explore alternatives to weight-promoting antidepressants like paroxetine, such as bupropion, which may support weight control.

Beyond Adjustments: Chiropractic and Integrative Healthcare- Video

The Role of Integrative Chiropractic Care in Obesity Management

Although obesity care is often viewed through a metabolic lens, neuromusculoskeletal health is pivotal for adherence, function, and long-term success. My integrative chiropractic protocols are embedded within a medical framework and address several key areas to support metabolic health.

• Segmental Dysfunction and Postural Stress: Restoring spinal and pelvic alignment reduces nociceptive (pain) signaling and modulates autonomic tone. Reduced pain and improved biomechanics lower sympathetic overdrive, supporting better glycemic control and blood pressure via autonomic balance.
• Soft Tissue and Myofascial Interventions: Improving fascial glide and reducing trigger points enhances range of motion and reduces pain, which is critical for increasing physical activity.
• Breathing Biomechanics: Thoracic mobility and rib cage mechanics impact ventilatory efficiency. Optimizing these can improve exercise tolerance, enhance vagal tone, and improve sleep quality.
• Proprioceptive Training and Motor Control: Neuromuscular re-education enhances joint stability and movement patterns, reducing injury risk during new activity regimens and increasing non-exercise activity thermogenesis (NEAT).

In my clinical observations, when we align chiropractic care with metabolic and behavioral strategies, patients demonstrate higher adherence rates, better mood, and improved sleep. Pain reduction and movement confidence are linchpins in sustained weight management.

Case Journeys: Bringing It All Together

To put this all together, let’s look at two case studies that mirror many patients we see, demonstrating our stepwise, evidence-based treatment plans.

Case 1: Natasha’s Preconception Journey

Natasha, a 33-year-old with Class III obesity (BMI 40.9), prediabetes, hypertension, and a history of preeclampsia, came to us to reduce her weight before a second pregnancy.

Stepwise Treatment Plan:

Our goal was a 1-2 year journey to reverse her metabolic dysfunction before conception.

1. Nutrition: A reduced-carbohydrate eating plan with high protein and fiber.
2. Physical Activity: Started with 10 minutes of walking, three days a week, gradually building to daily sessions and resistance training.
3. Medication (Under Dr. Cardenas’s oversight): Started Metformin ER for severe insulin resistance and then introduced Tirzepatide, titrating up as tolerated.

Two Years Later: The Transformation

• BMI: Reduced from 40.9 to 8.
• Labs: Her fasting insulin, A1C, lipids, and liver enzymes all normalized.

Preparing for Pregnancy:

• We discontinued the Tirzepatide with a two-month washout period.
• To minimize weight regain during this bridge period, we continued Metformin and her lifestyle plan, and temporarily added low-dose Phentermine (which was also stopped before attempting conception).
• Four months after stopping all non-pregnancy-safe medications, Natasha conceived.

She had an uneventful pregnancy, a planned C-section, and is now successfully breastfeeding, supported by our team and her high-risk OB. Natasha’s story is a powerful testament to what is possible with a dedicated, integrative, and patient-centered approach.

Case 2: Devon’s Path with Combination Therapy

Devon, age 40, presented with class III obesity, hypertension, prediabetes, and persistent hunger despite intermittent fasting. He wanted a non-surgical path.

Foundational Medical Plan:

• Started atorvastatin for hyperlipidemia, metformin for prediabetes, and vitamin D for deficiency.
• We restructured his nutrition to include at least two protein-prioritized meals within his fasting window.
• Before considering phentermine due to his hypertension risk, we obtained a baseline EKG and clearance from cardiology—an essential safety step.

Trajectory and Titration:

• Devon initially lost ~30 pounds on a GLP-1 agonist. Over time, due to insurance changes and persistent hunger, we transitioned him to Tirzepatide and added phentermine and topiramate to enhance appetite and control cravings.
• This layered approach addresses multiple nodes: gut-brain satiety signals (incretins), cortical reward circuits (topiramate), and central hunger signals (phentermine).
• Devon ultimately maintained a ~65-pound weight reduction (~20% total body weight), with broad lab normalization.

Integrative Chiropractic Support for These Cases

For both Natasha and Devon, chiropractic care was a driver of success; for Natasha, improved pelvic alignment reduced pain that had been a barrier to exercise. For Devon, addressing thoracolumbar mobility and hip-hinge mechanics enabled him to engage in safe resistance training. For both, breathwork and mobility drills helped reduce stress, improve sleep, and enhance their readiness for activity.

Closing Perspective: Obesity Care Is a Marathon, Not a Sprint

From Natasha’s metabolic stabilization to Devon’s long-term combination therapy, these journeys show that chronic obesity care succeeds through:

• Thoughtful sequencing of metabolic, pharmacologic, and behavioral
• Interdisciplinary teamwork—internal medicine oversight, chiropractic integration, functional medicine personalization, and rehabilitation.
• Persistent follow-up and data-driven adjustments.
• Patient-centered respect, including transparent discussions about all options, including bariatric surgery, which remains the gold standard for durable weight reduction in severe obesity.

In our clinic, the partnership among chiropractic care, internal medicine oversight, and functional medicine creates a safe, evidence-based pathway in which each discipline amplifies the others. Dr. Cardenas’s decades of internal medicine experience ensure safety and precision in medical decisions; my integrative chiropractic and functional medicine work ensures the body can move, sleep, and heal; and our rehabilitation services ensure injuries do not derail progress. By treating obesity as the complex, chronic disease it is, we can help patients transform not only their weight but also their mobility, resilience, and long-term health trajectories.

References

• Apovian, C. M., Aronne, L. J., Bessesen, D. H., et al. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Arcelus, J., Mitchell, A. J., Wales, J., & Nielsen, S. (2011). Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Archives of General Psychiatry, 68(7), 724-731.
• Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2019). 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. Circulation, 140(11), e596-e646.
• Azziz, R., Carmina, E., Chen, Z., et al. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, 16057.
• Black, P. H., & Garbutt, L. D. (2002). Stress, inflammation and cardiovascular disease. Journal of Psychosomatic Research, 52(1), 1-23.
• Blumenthal, S. R., Castro, V. M., Clements, C. C., et al. (2014). An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry, 71(8), 889-896.
• Bouillon, R., Marcocci, C., Carmeliet, G., et al. (2019). Skeletal and extraskeletal actions of vitamin D: Current evidence and outstanding questions. Endocrine Reviews, 40(4), 1109–1151.
• Bronfort, G., Haas, M., Evans, R., Leininger, B., & Triano, J. (2010). Effectiveness of manual therapies: the UK evidence report. Chiropractic & osteopathy, 18(1), 3.
• Chung, F., Abdullah, H. R., & Liao, P. (2016). STOP-Bang Questionnaire: A practical approach to screen for obstructive sleep apnea. Chest, 149(3), 631-638.
• Colberg, S. R., Sigal, R. J., Yardley, J. E., et al. (2016). Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. Diabetes Care, 39(11), 2065–2079.
• Correll, C. U., Maayan, L., Schepker, C., et al. (2013). Antipsychotic-induced weight gain: a comprehensive research synthesis. JAMA Psychiatry, 70(6), 622–632.
• Davies, M. J., D’Alessio, D. A., Fradkin, J., et al. (2018). Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669–2701.
• Feinman, R. D., Pogozelski, W. K., Astrup, A., et al. (2015). Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition, 31(1), 1–13.
• Francis, E. C., & Moran, L. J. (2019). Metformin in polycystic ovary syndrome: a guide to clinical practice. Clinical endocrinology, 91(5), 621-631.
• Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilization and incidence of weight gain during 10 years’ follow-up: population-based cohort study. BMJ, 361, k1951.
• Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22(Supplement 3), 1-203.
• Gottlieb, E. J., Malhotra, A., Grunstein, R. R., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine.
• Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-masked, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605.
• Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082–e1143.
• Hall, K. D., & Guo, J. (2017). Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology, 152(7), 1718-1727.
• Haskell, W. L., Lee, I. M., Pate, R. R., et al. (2007). Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation, 116(9), 1081.
• Hirschfeld, R. M., Williams, J. B., Spitzer, R. L., et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873-1875.
• Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444(7121), 860-867.
• Hudson, J. I., Guerdjikova, A. I., McElroy, S. L., et al. (2017). A controlled study of lisdexamfetamine dimesylate for the treatment of binge eating disorder in adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 56(8), 661-669.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
• Jensterle, M., Kocjan, T., Kravos, N. A., et al. (2015). Short-term intervention with liraglutide improves weight loss in women with polycystic ovary syndrome. Endocrine Research, 40(3), 146–151.
• Johns, M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 14(6), 540- 545.
• Johnson, T. S., & Schmitz, K. H. (2015). The role of physical activity in the management of obesity in pregnancy. Expert Review of Obstetrics & Gynecology, 10(5), 553–563.
• Kessler, R. C., Adler, L., Ames, M., et al. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychological Medicine, 35(2), 245-256.
• Kim, S. H., Park, M. J., & Lee, S. Y. (2016). Effects of metformin on antipsychotic-induced olanzapine-obesity and metabolic abnormalities in drug-naïve first-episode schizophrenia. Bipolar Disorders, 18(8), 642-650.
• Leidy, H. J., Clifton, P. M., Astrup, A., et al. (2015). The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition, 101(6), 1320S–1329S.
• Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 98(12), 4565-4592.
• Lévy, P., Kohler, M., & McNicholas, W. T. (2015). Obstructive sleep apnoea syndrome. Nature reviews Disease primers, 1(1), 1-19.
• Mancia, G., & Grassi, G. (2020). The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension, 38(9), 1686-1694.
• McElroy, S. L., Arnold, L. M., Shapira, N. A., et al. (2003). Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. American Journal of Psychiatry, 160(2), 255–261.
• McEwen, B. S. (2008). Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. European journal of pharmacology, 583(2-3), 174-185.
• Miller, G. E., Cohen, S., & Ritchey, A. K. (2002). Chronic psychological stress and the regulation of pro-inflammatory cytokines: a meta-analysis. Health psychology, 21(6), 531.
• Misra, M., & Klibanski, A. (2014). Endocrine consequences of anorexia nervosa. The lancet Diabetes & endocrinology, 2(7), 581-592.
• Morgan, J. F., Reid, F., & Lacey, J. H. (1999). The SCOFF questionnaire: assessment of a new screening tool for eating disorders. BMJ, 319(7223), 1467-1468.
• Poston, L., Bell, R., Croker, H., Flynn, A. C., Godfrey, K. M., Goff, L., … & UPBEAT consortium. (2015). Effect of a behavioral intervention in obese pregnant women (the UPBEAT study): a multicentre, randomized controlled trial. The Lancet Diabetes & Endocrinology, 3(10), 767–777.
• Rasmussen, K. M., & Yaktine, A. L. (Eds.). (2009). Weight Gain During Pregnancy: Reexamining the Guidelines. National Academies Press.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction 19(1), 41-47.
• Santacroce, N. G., Spagnuolo, R., & Vadalà, G. (2021). Disordered eating and obesity: a narrative review. Nutrients, 13(6), 1979.
• Schienle, A., Schäfer, A., Hermann, A., & Vaitl, D. (2009). Binge-eating disorder: reward sensitivity and brain activation to images of food. Biological Psychiatry, 65(8), 654-661.
• Serretti, A., & Mandelli, L. (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. The Journal of Clinical Psychiatry, 71(10), 1259-1272.
• Shivaram, H., Shivanand, S., & Seshadri, S. (2012). Obstructive sleep apnea: a risk factor for insulin resistance and glucose intolerance. Sleep Breath, 16(1), 227-233.
• Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. The Journal of Clinical Investigation, 116(7), 1793-1801.
• Simmons, D. (2016). Prevention of gestational diabetes mellitus: where are we now? Annals of the New York Academy of Sciences, 1372(1), 73–82.
• Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine, 166(10), 1092-1097.
• Taheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004). Short sleep duration is associated with lower leptin levels, higher ghrelin levels, and higher body mass index. PLoS medicine, 1(3), e62.
• Thomas, M. C., & Gregg, E. W. (2017). Metformin and digestive diseases. Diabetologia, 60(9), 1586-1593.
• Wang, X. S., Armstrong, M. E., Cairns, B. J., Key, T. J., & Travis, R. C. (2011). Shift work and chronic disease: the epidemiological evidence. Occupational Medicine, 61(2), 78-89.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.

SEO Tags

obesity care, integrative chiropractic care, PCOS and obesity, insulin resistance, GLP-1 therapies, semaglutide, tirzepatide, metformin PCOS, preconception counseling, pregnancy obesity risks, sleep apnea obesity, tirzepatide OSA evidence, stress and neuroinflammation, depression and obesity, eating disorders management, binge eating disorder, functional medicine obesity, El Paso Injury Medical Clinic, Dr. Alexander Jimenez DC, Dr. Maria Guadalupe Cardenas MD, Mission Plaza Injury Medical Clinic, metabolic health, women’s health PCOS, rehabilitation and weight loss, evidence-based obesity treatment, internal medicine collaboration, multidisciplinary obesity care, personal injury rehabilitation, STOP-BANG, Epigenetics, Generational Obesity, Breastfeeding Support, Postpartum Health